Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease

被引:221
作者
Lo Bianco, C
Schneider, BL
Bauer, M
Sajadi, A
Brice, A
Iwatsubo, T
Aebischer, P
机构
[1] Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol Lausanne, Inst Neurosci, CH-1015 Lausanne, Switzerland
[2] Hop La Pitie Salpetriere, U289, INSERM, F-75651 Paris, France
[3] Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan
[4] Univ Tokyo, Dept Neuropathol, Tokyo 1130033, Japan
关键词
gene therapy; lentivirus; neurodegenerative disease; Lewy body; neuroprotection;
D O I
10.1073/pnas.0405313101
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Parkinson's disease (PD) is characterized by a progressive loss of midbrain dopamine neurons and the presence of cytoplasmic inclusions called Lewy bodies. Mutations in several genes including alpha-synuclein and parkin have been linked to familial PD. The loss of parkin's E3-ligase activity leads to dopaminergic neuronal degeneration in early-onset autosomal recessive juvenile parkinsonism, suggesting a key role of parkin for dopamine neuron survival. To evaluate the potential neuroprotective role of parkin in the pathogenesis of PD, we tested whether overexpression of wild-type rat parkin could protect against the toxicity of mutated human A30P alpha-synuclein in a rat lentiviral model of PD. Animals overexpressing parkin showed significant reductions in alpha-synuclein-induced neuropathology, including preservation of tyrosine hydroxylase-positive cell bodies in the substantia nigra and sparing of tyrosine hydroxylase-positive nerve terminals in the striatum. The parkin-mediated neuroprotection was associated with an increase in hyperphosphorylated alpha-synuclein inclusions, suggesting a key role for parkin in the genesis of Lewy bodies. These results indicate that parkin gene therapy may represent a promising candidate treatment for PD.
引用
收藏
页码:17510 / 17515
页数:6
相关论文
共 49 条
[1]  
Beltramino C A, 1993, NIDA Res Monogr, V136, P101
[2]  
BELTRAMINO CA, 1993, NIDA RES MONOGR, V136, P126
[3]  
Blomer U, 1997, J VIROL, V71, P6641
[4]   Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1:: implications for Lewy-body formation in Parkinson disease [J].
Chung, KKK ;
Zhang, Y ;
Lim, KL ;
Tanaka, Y ;
Huang, H ;
Gao, J ;
Ross, CA ;
Dawson, VL ;
Dawson, TM .
NATURE MEDICINE, 2001, 7 (10) :1144-1150
[5]   Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct [J].
Conway, KA ;
Rochet, JC ;
Bieganski, RM ;
Lansbury, PT .
SCIENCE, 2001, 294 (5545) :1346-1349
[6]   Parkin's substrates and the pathways leading to neuronal damage [J].
Cookson, MR .
NEUROMOLECULAR MEDICINE, 2003, 3 (01) :1-13
[7]   Pathways to parkinsonism [J].
Cookson, MR .
NEURON, 2003, 37 (01) :7-10
[8]   Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice [J].
Cummings, CJ ;
Reinstein, E ;
Sun, YL ;
Antalffy, B ;
Jiang, YH ;
Ciechanover, A ;
Orr, HT ;
Beaudet, AL ;
Zoghbi, HY .
NEURON, 1999, 24 (04) :879-892
[9]   Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death [J].
Darios, F ;
Corti, O ;
Lücking, CB ;
Hampe, C ;
Muriel, MP ;
Abbas, N ;
Gu, WJ ;
Hirsch, EC ;
Rooney, T ;
Ruberg, M ;
Brice, A .
HUMAN MOLECULAR GENETICS, 2003, 12 (05) :517-526
[10]   Molecular pathways of neurodegeneration in Parkinson's disease [J].
Dawson, TM ;
Dawson, VL .
SCIENCE, 2003, 302 (5646) :819-822